Home LiteratureArticle Details
PMID: 28233803 Published · ppublish English Journal Article Review

Liquid biopsies come of age: towards implementation of circulating tumour DNA.

Nature reviews. Cancer ·Vol. 17 ·No. 4 ·2017-00-00 ·Pages 223-238

Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R, Rosenfeld N

Abstract

Improvements in genomic and molecular methods are expanding the range of potential applications for circulating tumour DNA (ctDNA), both in a research setting and as a 'liquid biopsy' for cancer management. Proof-of-principle studies have demonstrated the translational potential of ctDNA for prognostication, molecular profiling and monitoring. The field is now in an exciting transitional period in which ctDNA analysis is beginning to be applied clinically, although there is still much to learn about the biology of cell-free DNA. This is an opportune time to appraise potential approaches to ctDNA analysis, and to consider their applications in personalized oncology and in cancer research.

MeSH Terms
Biomarkers, Tumor/blood Biopsy Clonal Evolution DNA, Neoplasm/blood Early Detection of Cancer ErbB Receptors/genetics Humans Mutation Neoplasm Staging Neoplasms/genetics,pathology Precision Medicine
Chemicals
Biomarkers, Tumor DNA, Neoplasm ErbB Receptors
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Wan Jonathan C M
Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK. | Cancer Research UK Cambridge Centre, Cambridge CB2 0RE, UK.
Massie Charles
Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK. | Cancer Research UK Cambridge Centre, Cambridge CB2 0RE, UK.
Garcia-Corbacho Javier
Clinical Trials Unit, Clinic Institute of Haematological and Oncological Diseases, Hospital Clinic de Barcelona, IDIBAPs, Carrer de Villarroel, 170 Barcelona 08036, Spain.
Mouliere Florent
Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK. | Cancer Research UK Cambridge Centre, Cambridge CB2 0RE, UK.
Brenton James D
Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK. | Cancer Research UK Cambridge Centre, Cambridge CB2 0RE, UK.
Caldas Carlos
Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK. | Cancer Research UK Cambridge Centre, Cambridge CB2 0RE, UK. | Department of Oncology, University of Cambridge Hutchison-MRC Research Centre, Box 197, Cambridge Biomedical Campus, Cambridge CB2 0XZ, UK.
Pacey Simon
Cancer Research UK Cambridge Centre, Cambridge CB2 0RE, UK. | Department of Oncology, University of Cambridge Hutchison-MRC Research Centre, Box 197, Cambridge Biomedical Campus, Cambridge CB2 0XZ, UK.
Baird Richard
Cancer Research UK Cambridge Centre, Cambridge CB2 0RE, UK. | Department of Oncology, University of Cambridge Hutchison-MRC Research Centre, Box 197, Cambridge Biomedical Campus, Cambridge CB2 0XZ, UK.
Rosenfeld Nitzan
Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK. | Cancer Research UK Cambridge Centre, Cambridge CB2 0RE, UK.
References (220)
220 references, click to expand
  1. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status.
    J Thorac Oncol. 2014 Sep;9(9):1345-53 PMID: 25122430
  2. Exercise-induced increases in cell free DNA in human plasma originate predominantly from cells of the haematopoietic lineage.
    Exerc Immunol Rev. 2015;21:164-73 PMID: 25826002
  3. Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.
    Clin Cancer Res. 2016 Feb 15;22(4):915-22 PMID: 26459174
  4. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.
    Cancer. 2014 Dec 15;120(24):3896-901 PMID: 25103305
  5. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus.
    Sci Transl Med. 2010 Dec 8;2(61):61ra91 PMID: 21148127
  6. Noninvasive monitoring of infection and rejection after lung transplantation.
    Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):13336-41 PMID: 26460048
  7. Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer.
    Mol Oncol. 2014 Jul;8(5):927-41 PMID: 24698732
  8. Rapid clearance of fetal DNA from maternal plasma.
    Am J Hum Genet. 1999 Jan;64(1):218-24 PMID: 9915961
  9. Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients.
    PLoS One. 2016 Aug 16;11(8):e0161012 PMID: 27529345
  10. Detection and quantification of mutations in the plasma of patients with colorectal tumors.
    Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16368-73 PMID: 16258065
  11. Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer.
    J Mol Diagn. 2004 May;6(2):101-7 PMID: 15096565
  12. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis.
    Int J Cancer. 2002 Aug 10;100(5):542-8 PMID: 12124803
  13. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.
    Nat Commun. 2015 Nov 10;6:8839 PMID: 26554728
  14. Use of research biopsies in clinical trials: are risks and benefits adequately discussed?
    J Clin Oncol. 2013 Jan 1;31(1):17-22 PMID: 23129736
  15. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation.
    Clin Chem. 2002 Mar;48(3):421-7 PMID: 11861434
  16. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.
    N Engl J Med. 2014 Dec 25;371(26):2477-87 PMID: 25426838
  17. Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing.
    PLoS One. 2016 Nov 10;11(11):e0166354 PMID: 27832189
  18. TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study.
    Cancer Res. 2006 Jul 1;66(13):6871-6 PMID: 16818665
  19. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
    JAMA Oncol. 2015 May;1(2):149-57 PMID: 26181014
  20. Analysis of circulating tumor DNA to monitor metastatic breast cancer.
    N Engl J Med. 2013 Mar 28;368(13):1199-209 PMID: 23484797
  21. Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform.
    Oncotarget. 2015 Feb 10;6(4):2549-61 PMID: 25575824
  22. Serum tumor markers in breast cancer: are they of clinical value?
    Clin Chem. 2006 Mar;52(3):345-51 PMID: 16410341
  23. Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer.
    Oncotarget. 2016 May 17;7(20):29154-65 PMID: 27081078
  24. Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies.
    JAMA. 2015 Jul 14;314(2):162-9 PMID: 26168314
  25. Detection of K-ras mutation in sputum by mutant-allele-specific amplification (MASA).
    Hum Mutat. 1993;2(2):112-7 PMID: 8318987
  26. Cell-free nucleic acids as biomarkers in cancer patients.
    Nat Rev Cancer. 2011 Jun;11(6):426-37 PMID: 21562580
  27. Novel electrophoresis mechanism based on synchronous alternating drag perturbation.
    Electrophoresis. 2005 Jan;26(1):82-90 PMID: 15624147
  28. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.
    Sci Transl Med. 2015 Aug 26;7(302):302ra133 PMID: 26311728
  29. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.
    Science. 2014 Oct 10;346(6206):256-9 PMID: 25301631
  30. Sense and nonsense in the process of accreditation of a pathology laboratory.
    Virchows Arch. 2016 Jan;468(1):43-9 PMID: 26334197
  31. ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study.
    J Thorac Oncol. 2016 Oct;11(10):1682-9 PMID: 27468938
  32. The clearance and localization of nucleic acids by New Zealand and normal mice.
    Clin Exp Immunol. 1972 Dec;12(4):465-76 PMID: 4650369
  33. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
    Int J Cancer. 2014 Nov 1;135(9):2215-22 PMID: 24659028
  34. Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.
    Clin Cancer Res. 2016 Feb 1;22(3):567-74 PMID: 26446943
  35. Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.
    PLoS Med. 2016 Dec 20;13(12):e1002198 PMID: 27997533
  36. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.
    Nature. 2013 May 2;497(7447):108-12 PMID: 23563269
  37. The Long and Short of Circulating Cell-Free DNA and the Ins and Outs of Molecular Diagnostics.
    Trends Genet. 2016 Jun;32(6):360-371 PMID: 27129983
  38. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts.
    Nucleic Acids Res. 2010 Oct;38(18):6159-75 PMID: 20494973
  39. Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.
    Cancer Discov. 2016 Feb;6(2):147-153 PMID: 26644315
  40. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.
    Nature. 2012 Jun 28;486(7404):537-40 PMID: 22722843
  41. Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors.
    Genes Chromosomes Cancer. 2010 Nov;49(11):1062-9 PMID: 20725990
  42. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
    JAMA Oncol. 2016 Aug 1;2(8):1014-22 PMID: 27055085
  43. Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: A qualitative study.
    Gene. 2016 Sep 15;590(1):142-8 PMID: 27317895
  44. Evaluation of non-invasive prenatal testing (NIPT) for aneuploidy in an NHS setting: a reliable accurate prenatal non-invasive diagnosis (RAPID) protocol.
    BMC Pregnancy Childbirth. 2014 Jul 16;14:229 PMID: 25027965
  45. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations.
    Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8817-22 PMID: 12857956
  46. Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care.
    Clin Cancer Res. 2016 Jun 15;22(12):3067-77 PMID: 26847055
  47. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis.
    Clin Cancer Res. 1999 Oct;5(10):2689-92 PMID: 10537330
  48. Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma.
    Exp Mol Pathol. 2015 Dec;99(3):485-91 PMID: 26407762
  49. Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.
    Ann Oncol. 2017 Apr 1;28(4):784-790 PMID: 28104619
  50. Detection and quantification of rare mutations with massively parallel sequencing.
    Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9530-5 PMID: 21586637
  51. Detection of Clonal and Subclonal Copy-Number Variants in Cell-Free DNA from Patients with Breast Cancer Using a Massively Multiplexed PCR Methodology.
    Transl Oncol. 2015 Oct;8(5):407-416 PMID: 26500031
  52. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing.
    Clin Chem. 2013 Jan;59(1):211-24 PMID: 23065472
  53. Quantitative analysis of the transrenal excretion of circulating EBV DNA in nasopharyngeal carcinoma patients.
    Clin Cancer Res. 2008 Aug 1;14(15):4809-13 PMID: 18676752
  54. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.
    Sci Transl Med. 2016 Jul 6;8(346):346ra92 PMID: 27384348
  55. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease.
    EMBO Mol Med. 2015 Aug;7(8):1034-47 PMID: 25987569
  56. Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients.
    J Thorac Oncol. 2015 Oct;10(10):1437-43 PMID: 26295376
  57. Ultrasensitive Detection of Multiplexed Somatic Mutations Using MALDI-TOF Mass Spectrometry.
    J Mol Diagn. 2016 Jan;18(1):23-31 PMID: 26596526
  58. Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas.
    BMC Cancer. 2012 Sep 25;12:428 PMID: 23009708
  59. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.
    Nat Med. 2015 Jun;21(6):560-2 PMID: 25939061
  60. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
    Cancer Discov. 2016 May;6(5):479-91 PMID: 26969689
  61. Digital PCR.
    Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9236-41 PMID: 10430926
  62. The cancer bloodhounds.
    Nat Biotechnol. 2016 Nov 8;34(11):1090-1094 PMID: 27824838
  63. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin.
    Science. 2015 May 22;348(6237):880-6 PMID: 25999502
  64. Free DNA in the serum of cancer patients and the effect of therapy.
    Cancer Res. 1977 Mar;37(3):646-50 PMID: 837366
  65. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
    N Engl J Med. 2012 Mar 8;366(10):883-892 PMID: 22397650
  66. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing.
    PLoS Genet. 2014 Mar 27;10(3):e1004271 PMID: 24676216
  67. DNA released by leukemic cells contributes to the disruption of the bone marrow microenvironment.
    Oncogene. 2013 Oct 31;32(44):5201-9 PMID: 23222712
  68. Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA.
    PLoS One. 2015 Oct 16;10(10):e0140712 PMID: 26474073
  69. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
    Nat Med. 2015 Jul;21(7):795-801 PMID: 26030179
  70. Elevated cell-free plasma DNA level as an independent predictor of mortality in patients with severe traumatic brain injury.
    J Neurotrauma. 2014 Oct 1;31(19):1639-46 PMID: 24827371
  71. Direct quantification of cell-free, circulating DNA from unpurified plasma.
    PLoS One. 2014 Mar 03;9(3):e87838 PMID: 24595313
  72. Cellular barcoding: a technical appraisal.
    Exp Hematol. 2014 Aug;42(8):598-608 PMID: 24996012
  73. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients.
    Clin Cancer Res. 2009 Mar 15;15(6):2076-84 PMID: 19276259
  74. Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma.
    Cancer Biol Ther. 2006 Oct;5(10):1369-74 PMID: 16969071
  75. Measurement of deoxyribonuclease I activity in human tissues and body fluids by a single radial enzyme-diffusion method.
    Clin Chem. 1993 Mar;39(3):448-52 PMID: 8448855
  76. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.
    Sci Transl Med. 2015 Nov 11;7(313):313ra182 PMID: 26560360
  77. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.
    Sci Transl Med. 2016 Nov 9;8(364):364ra155 PMID: 27831904
  78. Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load.
    Transl Oncol. 2013 Jun 01;6(3):319-28 PMID: 23730412
  79. Cellular uptake of deoxyribonucleic acid by human tissue culture cells.
    Nature. 1959 Nov 7;184(Suppl 19):1505-6 PMID: 13826696
  80. Obesity-induced DNA released from adipocytes stimulates chronic adipose tissue inflammation and insulin resistance.
    Sci Adv. 2016 Mar 25;2(3):e1501332 PMID: 27051864
  81. Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes.
    Clin Biochem. 2016 Dec;49(18):1354-1360 PMID: 27129799
  82. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay.
    Oncotarget. 2016 Mar 1;7(9):9707-17 PMID: 26848768
  83. Changes in concentration of DNA in serum and plasma during storage of blood samples.
    Clin Chem. 2003 Jun;49(6 Pt 1):1028-9 PMID: 12766024
  84. Brain tumor mutations detected in cerebral spinal fluid.
    Clin Chem. 2015 Mar;61(3):514-22 PMID: 25605683
  85. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System.
    Mol Cancer Ther. 2016 Jun;15(6):1397-404 PMID: 27207774
  86. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia.
    Cancer Res. 1994 Jul 1;54(13):3568-73 PMID: 8012983
  87. Winnowing DNA for rare sequences: highly specific sequence and methylation based enrichment.
    PLoS One. 2012;7(2):e31597 PMID: 22355378
  88. Prenatal DNA diagnosis of a single-gene disorder from maternal plasma.
    Lancet. 2000 Sep 30;356(9236):1170 PMID: 11030304
  89. A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR.
    Clin Biochem. 2013 Oct;46(15):1561-5 PMID: 23769817
  90. Double-stranded DNA in exosomes: a novel biomarker in cancer detection.
    Cell Res. 2014 Jun;24(6):766-9 PMID: 24710597
  91. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types.
    Mol Oncol. 2015 Apr;9(4):783-90 PMID: 25579085
  92. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients.
    Clin Cancer Res. 2016 Nov 15;22(22):5497-5505 PMID: 27185373
  93. Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations.
    PLoS One. 2016 Jul 14;11(7):e0159094 PMID: 27416070
  94. Cancer therapy monitoring in xenografts by quantitative analysis of circulating tumor DNA.
    Biomarkers. 2012 Sep;17(6):498-506 PMID: 22616911
  95. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer.
    J Biol Chem. 2014 Feb 14;289(7):3869-75 PMID: 24398677
  96. Single-stranded DNA library preparation uncovers the origin and diversity of ultrashort cell-free DNA in plasma.
    Sci Rep. 2016 Jun 14;6:27859 PMID: 27297799
  97. FAST-SeqS: a simple and efficient method for the detection of aneuploidy by massively parallel sequencing.
    PLoS One. 2012;7(7):e41162 PMID: 22815955
  98. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Oct 1;34(28):3375-82 PMID: 27354477
  99. High fragmentation characterizes tumour-derived circulating DNA.
    PLoS One. 2011;6(9):e23418 PMID: 21909401
  100. High resolution size analysis of fetal DNA in the urine of pregnant women by paired-end massively parallel sequencing.
    PLoS One. 2012;7(10):e48319 PMID: 23118982
  101. Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study.
    Lancet Gastroenterol Hepatol. 2017 Jan;2(1):23-31 PMID: 28404010
  102. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
    Cancer Discov. 2016 Jan;6(1):36-44 PMID: 26546295
  103. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.
    Lancet Oncol. 2014 Nov;15(12):1379-88 PMID: 25439692
  104. Circulating DNA and DNase activity in human blood.
    Ann N Y Acad Sci. 2006 Sep;1075:191-6 PMID: 17108211
  105. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.
    Ann Oncol. 2015 Apr;26(4):731-6 PMID: 25628445
  106. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
    Nat Commun. 2016 Jun 10;7:11815 PMID: 27283993
  107. Single-stranded DNA library preparation for the sequencing of ancient or damaged DNA.
    Nat Protoc. 2013 Apr;8(4):737-48 PMID: 23493070
  108. Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma.
    Clin Cancer Res. 2016 Nov 15;22(22):5480-5486 PMID: 27482033
  109. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments.
    Proc Natl Acad Sci U S A. 2015 Oct 6;112(40):E5503-12 PMID: 26392541
  110. Real-time selective sequencing using nanopore technology.
    Nat Methods. 2016 Sep;13(9):751-4 PMID: 27454285
  111. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.
    Cancer Res. 2001 Feb 15;61(4):1659-65 PMID: 11245480
  112. Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer.
    Nat Commun. 2016 Jun 22;7:12008 PMID: 27328849
  113. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing.
    Nat Med. 2008 May;14(5):579-84 PMID: 18408729
  114. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection.
    Sci Transl Med. 2014 Jun 18;6(241):241ra77 PMID: 24944192
  115. Reduction in diagnostic and therapeutic interventions by non-invasive determination of fetal sex in early pregnancy.
    Prenat Diagn. 2005 Dec;25(12):1111-6 PMID: 16231296
  116. Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer.
    Am J Obstet Gynecol. 2005 Sep;193(3 Pt 1):662-7 PMID: 16150257
  117. Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism.
    Clin Chem. 2000 Aug;46(8 Pt 1):1078-84 PMID: 10926886
  118. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.
    Nat Med. 2014 May;20(5):548-54 PMID: 24705333
  119. Detection of cancer DNA in plasma of patients with early-stage breast cancer.
    Clin Cancer Res. 2014 May 15;20(10):2643-2650 PMID: 24504125
  120. Plasma collected from heparinized blood is not suitable for HCV-RNA detection by conventional RT-PCR assay.
    J Virol Methods. 1993 Apr;42(1):127-30 PMID: 7686556
  121. Noninvasive prenatal testing by nanopore sequencing of maternal plasma DNA: feasibility assessment.
    Clin Chem. 2015 Oct;61(10):1305-6 PMID: 26286915
  122. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.
    Clin Cancer Res. 2014 Mar 15;20(6):1698-1705 PMID: 24429876
  123. Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.
    Clin Cancer Res. 2015 Oct 15;21(20):4586-96 PMID: 26085511
  124. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.
    Ann Oncol. 2015 Aug;26(8):1715-22 PMID: 25851626
  125. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
    Lung Cancer. 2013 Mar;79(3):312-7 PMID: 23238036
  126. Nonhematopoietically derived DNA is shorter than hematopoietically derived DNA in plasma: a transplantation model.
    Clin Chem. 2012 Mar;58(3):549-58 PMID: 22052939
  127. Detection of circulating tumor DNA in early- and late-stage human malignancies.
    Sci Transl Med. 2014 Feb 19;6(224):224ra24 PMID: 24553385
  128. Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors.
    J Transl Med. 2016 Apr 19;14:95 PMID: 27095081
  129. Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer.
    EBioMedicine. 2016 Aug;10:117-23 PMID: 27377626
  130. Detection of ultra-rare mutations by next-generation sequencing.
    Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14508-13 PMID: 22853953
  131. Soluble normal and mutated DNA sequences from single-copy genes in human blood.
    Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):67-71 PMID: 8118388
  132. Neoplastic characteristics of the DNA found in the plasma of cancer patients.
    Oncology. 1989;46(5):318-22 PMID: 2779946
  133. Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer.
    Clin Chim Acta. 2014 Jun 10;433:284-9 PMID: 24685572
  134. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma.
    Clin Cancer Res. 2003 Aug 15;9(9):3254-9 PMID: 12960110
  135. MicroRNAs accurately identify cancer tissue origin.
    Nat Biotechnol. 2008 Apr;26(4):462-9 PMID: 18362881
  136. Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin.
    Cell. 2016 Jan 14;164(1-2):57-68 PMID: 26771485
  137. Pros: Can tissue biopsy be replaced by liquid biopsy?
    Transl Lung Cancer Res. 2016 Aug;5(4):420-3 PMID: 27655109
  138. Nuclear Acids In Human Blood Plasma.
    C R Seances Soc Biol Fil. 1948 Feb;142(3-4):241-3 PMID: 18875018
  139. PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients.
    Breast Cancer Res Treat. 2015 Apr;150(2):299-307 PMID: 25736040
  140. Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord.
    Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):9704-9 PMID: 26195750
  141. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors.
    Science. 1992 Apr 3;256(5053):102-5 PMID: 1566048
  142. Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.
    Lung Cancer. 2014 Apr;84(1):39-44 PMID: 24513263
  143. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients.
    Clin Chem. 2013 Dec;59(12):1722-31 PMID: 23938455
  144. Allele-specific enzymatic amplification of beta-globin genomic DNA for diagnosis of sickle cell anemia.
    Proc Natl Acad Sci U S A. 1989 Apr;86(8):2757-60 PMID: 2704745
  145. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
    N Engl J Med. 2017 Feb 16;376(7):629-640 PMID: 27959700
  146. Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing.
    Mol Oncol. 2014 Feb;8(1):150-8 PMID: 24220311
  147. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
    Nature. 2012 Jun 28;486(7404):532-6 PMID: 22722830
  148. The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA.
    Clin Cancer Res. 2017 May 15;23(10):2471-2477 PMID: 27827317
  149. Mitochondrial resequencing arrays detect tumor-specific mutations in salivary rinses of patients with head and neck cancer.
    Clin Cancer Res. 2007 Dec 15;13(24):7335-40 PMID: 18094415
  150. Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation.
    Ann N Y Acad Sci. 2006 Sep;1075:299-307 PMID: 17108224
  151. Subclonal diversification of primary breast cancer revealed by multiregion sequencing.
    Nat Med. 2015 Jul;21(7):751-9 PMID: 26099045
  152. Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer.
    Eur Urol. 2016 Jul;70(1):75-82 PMID: 26803478
  153. Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing.
    Genome Med. 2013 Apr 05;5(4):30 PMID: 23561577
  154. Circulating cell free DNA: Preanalytical considerations.
    Clin Chim Acta. 2013 Sep 23;424:222-30 PMID: 23727028
  155. Real-time, portable genome sequencing for Ebola surveillance.
    Nature. 2016 Feb 11;530(7589):228-232 PMID: 26840485
  156. A Minimally-invasive Blood-derived Biomarker of Oligodendrocyte Cell-loss in Multiple Sclerosis.
    EBioMedicine. 2016 Aug;10:227-35 PMID: 27381476
  157. Presence of fetal DNA in maternal plasma and serum.
    Lancet. 1997 Aug 16;350(9076):485-7 PMID: 9274585
  158. Inferring expressed genes by whole-genome sequencing of plasma DNA.
    Nat Genet. 2016 Oct;48(10):1273-8 PMID: 27571261
  159. Carrier molecules and extraction of circulating tumor DNA for next generation sequencing in colorectal cancer.
    Acta Medica (Hradec Kralove). 2016;59(2):54-8 PMID: 27526306
  160. RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics.
    Cancer Cell. 2015 Nov 9;28(5):666-676 PMID: 26525104
  161. Metastasis as an evolutionary process.
    Science. 2016 Apr 8;352(6282):169-75 PMID: 27124450
  162. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release.
    Clin Chim Acta. 2001 Nov;313(1-2):139-42 PMID: 11694251
  163. Direct measurement of cell-free DNA from serially collected capillary plasma during incremental exercise.
    J Appl Physiol (1985). 2014 Jul 15;117(2):119-30 PMID: 24876361
  164. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS).
    Nucleic Acids Res. 1989 Apr 11;17(7):2503-16 PMID: 2785681
  165. Molecular Triage of Premalignant Lesions in Liquid-Based Cervical Cytology and Circulating Cell-Free DNA from Urine, Using a Panel of Methylated Human Papilloma Virus and Host Genes.
    Cancer Prev Res (Phila). 2016 Dec;9(12):915-924 PMID: 27671338
  166. Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA.
    Ann Oncol. 2016 Oct;27(10):1959-65 PMID: 27502704
  167. Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening.
    BMC Med. 2016 Aug 24;14(1):126 PMID: 27558279
  168. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls.
    Pancreas. 1998 Jul;17(1):89-97 PMID: 9667526
  169. Identification of p53 gene mutations in bladder cancers and urine samples.
    Science. 1991 May 3;252(5006):706-9 PMID: 2024123
  170. A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.
    J Thorac Oncol. 2016 Oct;11(10):1690-700 PMID: 27468937
  171. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.
    Nat Commun. 2015 Nov 04;6:8760 PMID: 26530965
  172. Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC).
    PLoS One. 2016 Feb 26;11(2):e0150197 PMID: 26918901
  173. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.
    Br J Cancer. 2014 Jan 7;110(1):55-62 PMID: 24263064
  174. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery.
    Gut. 2016 Apr;65(4):625-34 PMID: 25654990
  175. Identification of tissue-specific cell death using methylation patterns of circulating DNA.
    Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):E1826-34 PMID: 26976580
  176. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer.
    Clin Cancer Res. 2010 Feb 15;16(4):1324-30 PMID: 20145159
  177. Rapid Short-Read Sequencing and Aneuploidy Detection Using MinION Nanopore Technology.
    Genetics. 2016 Jan;202(1):37-44 PMID: 26500254
  178. MinION Analysis and Reference Consortium: Phase 1 data release and analysis.
    F1000Res. 2015 Oct 15;4:1075 PMID: 26834992
  179. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing.
    Sci Transl Med. 2012 Nov 28;4(162):162ra154 PMID: 23197571
  180. Elimination of unaltered DNA in mixed clinical samples via nuclease-assisted minor-allele enrichment.
    Nucleic Acids Res. 2016 Nov 2;44(19):e146 PMID: 27431322
  181. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer.
    Cancer Res. 1994 Apr 1;54(7):1634-7 PMID: 8137272
  182. Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.
    Cancer Discov. 2015 Jul;5(7):713-22 PMID: 25934077
  183. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.
    Lung Cancer. 2015 Dec;90(3):509-15 PMID: 26494259
  184. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer.
    Ann Oncol. 2016 May;27(5):862-7 PMID: 26823523
  185. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.
    Ann Oncol. 2014 Sep;25(9):1729-35 PMID: 25009010
  186. Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA.
    Clin Biochem. 2015 Oct;48(15):993-8 PMID: 26234639
  187. Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells.
    Cancer Res. 2010 Jan 15;70(2):560-7 PMID: 20068178
  188. Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma.
    Nat Commun. 2015 May 11;6:6999 PMID: 25959588
  189. Exposure to low-dose ionizing radiation from medical imaging procedures.
    N Engl J Med. 2009 Aug 27;361(9):849-57 PMID: 19710483
  190. Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing.
    Cancer Res. 2012 Jul 15;72(14):3492-8 PMID: 22581825
  191. The value of serial plasma nuclear and mitochondrial DNA levels in patients with acute ischemic stroke.
    Clin Chim Acta. 2011 Feb 20;412(5-6):476-9 PMID: 21130757
  192. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.
    Sci Transl Med. 2013 Jan 9;5(167):167ra4 PMID: 23303603
  193. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade.
    J Immunother Cancer. 2014 Dec 16;2(1):42 PMID: 25516806
  194. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.
    Oncotarget. 2015 Dec 8;6(39):42008-18 PMID: 26524482
  195. Development of personalized tumor biomarkers using massively parallel sequencing.
    Sci Transl Med. 2010 Feb 24;2(20):20ra14 PMID: 20371490
  196. Integrated digital error suppression for improved detection of circulating tumor DNA.
    Nat Biotechnol. 2016 May;34(5):547-555 PMID: 27018799
  197. Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study.
    PLoS Med. 2016 Dec 27;13(12):e1002206 PMID: 28027320
  198. Commentary on tumor heterogeneity.
    Transl Lung Cancer Res. 2016 Aug;5(4):433-5 PMID: 27659489
  199. Plasma AR and abiraterone-resistant prostate cancer.
    Sci Transl Med. 2015 Nov 4;7(312):312re10 PMID: 26537258
  200. Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing.
    Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):18761-8 PMID: 24191000
  201. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance.
    Mutat Res. 2007 May-Jun;635(2-3):105-17 PMID: 17257890
  202. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer.
    Int J Cancer. 2013 Jul 15;133(2):346-56 PMID: 23319339
  203. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution.
    Science. 2014 Oct 10;346(6206):251-6 PMID: 25301630
  204. Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing.
    JAMA Oncol. 2015 Sep;1(6):814-9 PMID: 26355862
  205. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.
    Sci Transl Med. 2012 May 30;4(136):136ra68 PMID: 22649089
  206. Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer.
    Oncotarget. 2017 Feb 14;8(7):12501-12516 PMID: 27980215
  207. Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel In Vivo Device for Capturing Circulating Tumor Cells.
    Clin Cancer Res. 2016 May 1;22(9):2197-206 PMID: 26667488
  208. Non-invasive prenatal testing: a review of international implementation and challenges.
    Int J Womens Health. 2015 Jan 16;7:113-26 PMID: 25653560
  209. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.
    Nat Med. 2014 Apr;20(4):430-5 PMID: 24658074
  210. Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.
    Genome Res. 2015 Jun;25(6):814-24 PMID: 25963125
  211. Origins, structures, and functions of circulating DNA in oncology.
    Cancer Metastasis Rev. 2016 Sep;35(3):347-76 PMID: 27392603
  212. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.
    Clin Cancer Res. 2009 Apr 15;15(8):2630-6 PMID: 19351754
  213. Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program.
    Cancer. 2013 May 15;119(10):1838-44 PMID: 23436393
  214. Differential strand separation at critical temperature: a minimally disruptive enrichment method for low-abundance unknown DNA mutations.
    Nucleic Acids Res. 2013 Feb 1;41(3):e50 PMID: 23258702
  215. Nanopore sequencing detects structural variants in cancer.
    Cancer Biol Ther. 2016;17(3):246-53 PMID: 26787508
  216. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
    Clin Cancer Res. 2006 Jul 1;12(13):3915-21 PMID: 16818687
  217. Rapid Identification of Plasma DNA Samples with Increased ctDNA Levels by a Modified FAST-SeqS Approach.
    Clin Chem. 2015 Jun;61(6):838-49 PMID: 25896989
  218. Digital PCR for the molecular detection of fetal chromosomal aneuploidy.
    Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13116-21 PMID: 17664418
  219. PCR-detection of tumor-derived p53 DNA in cerebrospinal fluid.
    Am J Clin Pathol. 1995 Apr;103(4):404-8 PMID: 7726135
  220. Origin and prognostic value of circulating KRAS mutations in lung cancer patients.
    Cancer Lett. 2007 Sep 8;254(2):265-73 PMID: 17449174
Article Info
Journal
Nature reviews. Cancer
Abbr.
Nat Rev Cancer
ISSN
1474-1768
DOI
10.1038/nrc.2017.7
Published
2017-00-00
Epub
2017-00-24
Pages
223-238
Language
English
Region
England
NLM ID
101124168
Subset
IM
Grants
Cancer Research UK · 15601 · United Kingdom
Cancer Research UK · A15601 · United Kingdom
Cancer Research UK · A20240 · United Kingdom
Cancer Research UK · A11906 · United Kingdom
External Links
PubMed source DOI: 10.1038/nrc.2017.7 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2